

October 19, 2018



Heat Biologics CEO to Participate in Panel Presentation at The Cellular "Living Drug" Revolution Summit in New York City

DURHAM, NC / ACCESSWIRE / October 19, 2018/ [Heat Biologics, Inc.](#) (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced it will present at The Cellular "Living Drug" Revolution Summit being held next Thursday, October 25, 2018, at 6:00 PM, ET in New York City. John Prendergast, PH.D., Heat's Lead Independent Director, will be presenting on the panel.

The event brings executives from leading cell therapy companies together to discuss where the industry is headed and how their companies, individually and collectively, are helping advance the industry into a new era. Investors interested in attending the event can register at: <https://investmentstrategiesinanewmedi.splashthat.com/>

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immunomodulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our *ComPACT* technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. We also have numerous pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.

Media and Investor Relations Contact

David Waldman

+1 919 289 4017

investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.

